Contribute Try STAT+ Today

Good morning, one and all. Damian Garde here, filling in for Ed Silverman in the morning aftermath of yet another nigh-on-Biblical bout of rain. The weekend is ever closer, but in its way is another busy work day of deadlines and projects and video calls that could just as well have been emails. Here as always are some tidbits to help you along. And if you hear anything interesting, do let us know. …

Even top FDA officials were surprised by the agency’s decision to initially grant a broad label to the Biogen (BIIB) treatment for Alzheimer’s disease, STAT tells us. Two senior staffers who were present at a key FDA meeting said they supported the idea of an accelerated approval for the treatment, Aduhelm, but were caught off guard when the agency approved it for all people with Alzheimer’s, rather than those who matched the patients in the clinical studies. One said they would never have supported the faster approval process had they known the agency was considering such a broad patient population.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Create a display name to comment

This name will appear with your comment